AN2 Therapeutics (ANTX) Payables (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Payables data on file, last reported at $2.6 million in Q1 2026.

• Payables for Q1 2026 came in at $2.6 million, down 14.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 14.9% YoY), and the FY2025 annual result was $3.0 million, down 8.92% from the prior year.
• Payables declined to $2.6 million in Q1 2026 per ANTX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Payables peaked at $4.9 million in Q3 2023 and troughed at $1.4 million in Q3 2022.
• A 5-year average of $2.6 million and a median of $2.6 million in 2022 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2024: Payables surged 238.68% in 2023, then sank 64.92% in 2024.
• A 5-year view of Payables shows it stood at $2.1 million in 2022, then increased by 26.11% to $2.7 million in 2023, then gained by 23.95% to $3.3 million in 2024, then slipped by 8.92% to $3.0 million in 2025, then slipped by 13.44% to $2.6 million in 2026.
• Business Quant data shows ANTX's Payables at $2.6 million in Q1 2026, $3.0 million in Q4 2025, and $2.2 million in Q3 2025.